Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Avet-Loiseau, H. | - |
dc.contributor.author | Durie, B. G. M. | - |
dc.contributor.author | Cavo, M. | - |
dc.contributor.author | Attal, M. | - |
dc.contributor.author | Gutierrez, N. | - |
dc.contributor.author | Haessler, J. | - |
dc.contributor.author | Goldschmidt, H. | - |
dc.contributor.author | Hajek, R. | - |
dc.contributor.author | Lee, J. H. | - |
dc.contributor.author | Sezer, O. | - |
dc.contributor.author | Barlogie, B. | - |
dc.contributor.author | Crowley, J. | - |
dc.contributor.author | Fonseca, R. | - |
dc.contributor.author | Testoni, N. | - |
dc.contributor.author | Ross, F. | - |
dc.contributor.author | Rajkumar, S. V. | - |
dc.contributor.author | Sonneveld, P. | - |
dc.contributor.author | Lahuerta, J. | - |
dc.contributor.author | Moreau, P. | - |
dc.contributor.author | Morgan, G. | - |
dc.date.available | 2020-02-29T00:43:14Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 0887-6924 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14700 | - |
dc.description.abstract | The combination of serum beta 2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The aim of this study was to assess the independent contributions of ISS stage and cytogenetic abnormalities in predicting outcomes. A retrospective analysis of international studies looking at both ISS and cytogenetic abnormalities was performed in order to assess the potential role of combining ISS stage and cytogenetics to predict survival. This international effort used the International Myeloma Working Group database of 12 137 patients treated worldwide for myeloma at diagnosis, of whom 2309 had cytogenetic studies and 5387 had analyses by fluorescent in situ hybridization (iFISH). Comprehensive analyses used 2642 patients with sufficient iFISH data available. Using the comprehensive iFISH data, combining both t(4;14) and deletion (17p), along with ISS stage, significantly improved the prognostic assessment in terms of progression-free survival and overall survival. The additional impact of patient age and use of high-dose therapy was also demonstrated. In conclusion, the combination of iFISH data with ISS staging significantly improves risk assessment in myeloma. Leukemia (2013) 27, 711-717; doi:10.1038/leu.2012.282 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.isPartOf | LEUKEMIA | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | DIAGNOSED MULTIPLE-MYELOMA | - |
dc.subject | HIGH-DOSE THERAPY | - |
dc.subject | INTERGROUPE FRANCOPHONE | - |
dc.subject | PLUS DEXAMETHASONE | - |
dc.subject | BORTEZOMIB | - |
dc.subject | SURVIVAL | - |
dc.subject | SYSTEM | - |
dc.subject | PROGNOSIS | - |
dc.subject | T(4/14) | - |
dc.title | Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000316587300026 | - |
dc.identifier.doi | 10.1038/leu.2012.282 | - |
dc.identifier.bibliographicCitation | LEUKEMIA, v.27, no.3, pp.711 - 717 | - |
dc.identifier.scopusid | 2-s2.0-84875209671 | - |
dc.citation.endPage | 717 | - |
dc.citation.startPage | 711 | - |
dc.citation.title | LEUKEMIA | - |
dc.citation.volume | 27 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Lee, J. H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | myeloma | - |
dc.subject.keywordAuthor | cytogenetics | - |
dc.subject.keywordAuthor | prognostic | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | DIAGNOSED MULTIPLE-MYELOMA | - |
dc.subject.keywordPlus | HIGH-DOSE THERAPY | - |
dc.subject.keywordPlus | INTERGROUPE FRANCOPHONE | - |
dc.subject.keywordPlus | PLUS DEXAMETHASONE | - |
dc.subject.keywordPlus | BORTEZOMIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | T(4/14) | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.